Triazolopyrimidine compounds and uses thereof

1. A compound of Formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

is a single bond or a double bond;

R 1 and R 2 are independently H or halogen;

R 3 is independently selected from: halogen, phenyl, and a 5- to 6-membered heteroaryl comprising carbon atoms and 1-4 heteroatoms selected from N, NR a , O, and S(O) p ; wherein said phenyl and heteroaryl are substituted with 0-3 R 3A ;

each R 3A is independently selected from: halogen, CN, —(O) m —(C 1 -C 6 alkyl substituted with 0-1 R 3B ), C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, R 3C , —OR 3C , —C(═O)R 3D , NR 3E R 3F , —C(═O)NR 3E R 3F , —NHC(═O)R 3D , —S(═O) 2 R 3D , —S(═O) 2 NR 3E R 3F , —NHS(═O) 2 (C 1 -C 4 alkyl), and —CR 3C R 3E R 3G ;

R 3B is independently selected from: OH, NR e R f , C 1 -C 4 alkoxy, —C(═O)NR e R f , —S(═O) 2 (C 1 -C 4 alkyl), —NHC(═O)(C 1 -C 4 alkyl), and a 5- to 6-membered heterocycloalkyl comprising carbon atoms and 1-2 heteroatoms selected from N, NR a , O, and S(O) p ; wherein said heterocycloalkyl is substituted with 0-2 R c ;

each R 3C is independently selected from: C 3 -C 6 cycloalkyl, phenyl, and a 4- to 7-membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, NR a , O, and S(O) p ; wherein each moiety is substituted with 0-2 R c ;

each R 3D is independently selected from: C 1 -C 4 alkyl and R 3C ;

R 3E and R 3G are, at each occurrence, independently selected from: H and C 1 -C 4 alkyl;

each R 3F is independently selected from: H and C 1 -C 4 alkyl substituted with 0-1 R d ;

R 4 is independently selected from: H, halogen and C 1 -C 4 alkyl;

R 5 is independently selected from OH and C 1 -C 4 alkyl;

each R a is independently selected from: H, →O, C 1 -C 4 alkyl substituted with 0-1 R b , —C(═O)H, —C(═O)(C 1 -C 4 alkyl), —CO 2 (C 1 -C 4 alkyl), C 3 -C 6 cycloalkyl, and benzyl;

R b is independently selected from: halogen, OH and C 1 -C 4 alkoxy;

each R c is independently selected from: ═O, halogen, OH, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, and C 1 -C 4 haloalkoxy;

R d is independently selected from: OH and NR e R f ;

R e and R f are, at each occurrence, independently selected from: H and C 1 -C 4 alkyl;

each p is independently selected from 0, 1 and 2; and

m and n are, at each occurrence, independently selected from 0 and 1.

2. A compound or a pharmaceutically acceptable salt thereof, according to claim 1 , wherein:

each R 3A is independently selected from: halogen, CN, —(O) m —(C 1 -C 4 alkyl substituted with 0-1 R 3B ), C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, R 3C , —C(═O)R 3D , NR 3E R 3F , —C(═O)NR 3E R 3F , —S(═O) 2 R 3D , —S(═O) 2 NHR 3F , —NHS(═O) 2 (C 1 -C 4 alkyl), —O—C 3 -C 6 cycloalkyl, and

R a is independently selected from: H, →O, C 1 -C 4 alkyl substituted with 0-1 R b , —C(═O)H, —C(═O)(C 1 -C 4 alkyl), —CO 2 (C 1 -C 4 alkyl), and C 3 -C 6 cycloalkyl;

R 4 is H;

m is independently selected from 0 and 1; and

n is 0.

3. A compound or a pharmaceutically acceptable salt thereof, according to claim 2 , wherein:

R 1 is independently H or F;

R 2 is H; and

R 3 is independently selected from: phenyl, and a 6-membered heteroaryl comprising carbon atoms and 1-2 heteroatoms selected from N and NR a ; wherein said phenyl and heteroaryl are substituted with 0-3 R 3A .

4. A compound or a pharmaceutically acceptable salt thereof, according to claim 3 , wherein:

R 3 is independently selected from: phenyl, pyridyl, pyrimidyl, pyridazinyl and pyrazinyl; wherein each moiety is substituted with 0-3 R 3A .

5. A compound or a pharmaceutically acceptable salt thereof, according to claim 4 , wherein:

R 3 is independently selected from:

6. A compound or a pharmaceutically acceptable salt thereof, according to claim 4 , wherein:

R 3 is independently selected from:

each R 3A is independently selected from: halogen, CN, —(O) m —(C 1 -C 4 alkyl substituted with 0-1 R 3B ), C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, —C(═O)NH 2 , —C(═O)NH(C 1 -C 4 alkyl), —C(═O)N(C 1 -C 4 alkyl) 2 , —C(═O)N(C 1 -C 4 alkyl)(CH 2 ) 2 N(C 1 -C 4 alkyl) 2 , —CH 2 NHC(═O)(C 1 -C 4 alkyl), —S(═O) 2 R 3D , —S(═O) 2 NH(C 1 -C 4 alkyl substituted with 0-1 OH), —NHS(═O) 2 (C 1 -C 4 alkyl), NH 2 , —NH(C 1 -C 4 alkyl), —N(C 1 -C 4 alkyl) 2 , C 3 -C 6 cycloalkyl,

R 3B is independently selected from: OH, NH 2 , NH(C 1 -C 4 alkyl), N(C 1 -C 4 alkyl) 2 , C 1 -C 4 alkoxy, —C(═O)N(C 1 -C 4 alkyl) 2 , —S(═O) 2 (C1-C4 alkyl),

R 3D is independently selected from: C 1 -C 4 alkyl and 1H-piperidin-4-yl; and

each R a is independently selected from: H, C 1 -C 4 alkyl, —C(═O)H, —C(═O)(C 1 -C 4 alkyl), and —CO 2 (C 1 -C 4 alkyl).

7. A compound or a pharmaceutically acceptable salt thereof, according to claim 6 , wherein:

R 3 is independently selected from:

each R 3A is independently selected from: halogen, CN, —(O) m —(C 1 -C 4 alkyl substituted with 0-1 R 3B ), C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, —C(═O)NH 2 , —C(═O)NH(C 1 -C 4 alkyl), —C(═O)N(C 1 -C 4 alkyl) 2 , —C(═O)N(C 1 -C 4 alkyl)(CH 2 ) 2 N(C 1 -C 4 alkyl) 2 , —CH 2 NHC(═O)(C 1 -C 4 alkyl), —S(═O) 2 (C 1 -C 4 alkyl), NH 2 , NH(C 1 -C 4 alkyl), N(C 1 -C 4 alkyl) 2 , C 3 -C 6 cycloalkyl,

R 3B is independently selected from: OH, N(C 1 -C 4 alkyl) 2 , C 1 -C 4 alkoxy, —C(═O)N(C 1 -C 4 alkyl) 2 , —S(═O) 2 (C 1 -C 4 alkyl),

 and

each R a is independently selected from: H, C 1 -C 4 alkyl, —C(═O)H, —C(═O)(C 1 -C 4 alkyl), and —CO 2 (C 1 -C 4 alkyl).

8. A compound or a pharmaceutically acceptable salt thereof, according to claim 7 , wherein:

each R 3A is independently selected from: F, CI, CH 3 , —CH 2 OH, CH 2 F, CHF 2 , CF 3 , CN, —OCH 3 , —OCH 2 CH 3 , —OCH(CH 3 ) 2 , —OCHF 2 , —C(═O)N(CH 3 ) 2 , —CH 2 NHC(═O)CH 3 , —S(═O) 2 CH 3 , NH 2 , cyclopropyl,

9. A compound or a pharmaceutically acceptable salt thereof, according to claim 1 , wherein said compound is of Formula (IA-1):

or a pharmaceutically acceptable salt thereof, wherein:

R 1 is independently H or F; and

R 3A is independently selected from: F, CH 3 , —CH 2 OH, CH 2 F, CHF 2 , CF 3 , and —OCH 3 .

10. A compound or a pharmaceutically acceptable salt thereof, according to claim 9 , wherein:

R 1 is F.

11. A compound according to claim 1 , wherein:

R 1 is independently H or F;

R 2 is H;

R 3 is independently a 5-membered heteroaryl comprising carbon atoms and 1-4 heteroatoms selected from N, NR a , O, and S(O) p ; wherein said heteroaryl is substituted with 0-3 R 3A ; and

R a is independently selected from: H, C 1 -C 4 alkyl substituted with 0-1 R b , —C(═O)H, —C(═O)(C 1 -C 4 alkyl), —CO 2 (C 1 -C 4 alkyl), C 3 -C 6 cycloalkyl, and benzyl.

12. A compound or a pharmaceutically acceptable salt thereof, according to claim 11 , wherein:

R 3 is independently selected from:

13. A compound or a pharmaceutically acceptable salt thereof, according to claim 1 , wherein said compound is selected from Examples 1 to 245.

14. A compound according to claim 1 , wherein said compound is selected from:

or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical composition, comprising one or more pharmaceutically acceptable carriers and a compound or a pharmaceutically acceptable salt thereof, according to claim 1 .

16. The pharmaceutical composition of claim 15 further comprising at least one additional therapeutic agent.

17. The pharmaceutical composition of claim 16 where said at least one additional therapeutic agent is selected from other anti-cancer agents, immunomodulators, anti-allergic agents, anti-emetics, pain relievers, cytoprotective agents, and combinations thereof.

18. A method for treating a disease or disorder mediated by EED and/or PRC2, comprising the step of administering to a subject in need of such treatment a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, according to claim 1 ; wherein said disease or disorder is selected from diffuse large B cell lymphoma, follicular lymphoma, other lymphomas, leukemia, multiple myeloma, mesothelioma, gastric cancer, malignant rhabdoid tumor, hepatocellular carcinoma, prostate cancer, breast carcinoma, bile duct and gallbladder cancers, bladder carcinoma, brain tumors including neuroblastoma, schwannoma, glioma, glioblastoma and astrocytoma, cervical cancer, colon cancer, melanoma, endometrial cancer, esophageal cancer, head and neck cancer, lung cancer, nasopharyngeal carcinoma, ovarian cancer, pancreatic cancer, renal cell carcinoma, rectal cancer, thyroid cancers, parathyroid tumors, uterine tumors, and soft tissue sarcomas.

19. A compound according to claim 1 , wherein said compound is 8-(1,3-dimethyl-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine, or a pharmaceutically acceptable salt thereof.

20. A compound according to claim 1 , wherein said compound is N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine, or a pharmaceutically acceptable salt thereof.